6 completed, 4 not yet recruiting, 3 recruiting, 1 active not recruiting. 2 Phase 3, 1 Not applicable, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Obstructive Hypertrophic Cardiomyopathy (oHCM): new trials by email Literature Review of Obstructive Hypertrophic Cardiomyopathy (oHCM) trials Research Report on Obstructive Hypertrophic Cardiomyopathy (oHCM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy Beta-Blocker Sequential Tapering and Discontinuation, Beta-Blocker Baseline Stable-Dose Maintenance - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Not applicable | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 286 | 2026-12-01 | 2026-09-11 |
| Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Not yet recruiting | Bristol-Myers Squibb | 800 | 2026-09-30 | 2026-09-29 | |
| Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 4 | Not yet recruiting | Second Affiliated Hospital of Nanchang University | 115 | 2026-09-01 | 2026-09-08 |
| Biological Collection for the Purpose of Exploring Genetic and Clinical-biological Factors Associated With Variability in Response to Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy (oHCM) | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 300 | 2026-02-05 | 2026-02-27 | |
| Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Recruiting | Bristol-Myers Squibb | 362 | 2026-01-15 | 2026-04-29 | |
| Ademetionine in Obstructive Hypertrophic Cardiomyopathy Ademetionine 1,4-Butanedisulfonate, Placebo - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 2 | Recruiting | China National Center for Cardiovascular Diseases | 44 | 2026-01-01 | 2026-03-20 |
| Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Recruiting | Bristol-Myers Squibb | 200 | 2025-05-21 | 2026-02-03 | |
| Real-World Effectiveness of Mavacamten in Canada Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | Bristol-Myers Squibb | 115 | 2024-06-24 | 2025-12-04 | |
| Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy mavacamten - Hypertrophic Cardiomyopathy (HCM), Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | Chinese Academy of Medical Sciences, Fuwai Hospital | 222 | 2024-01-01 | 2026-04-17 | |
| A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Active not recruiting | Bristol-Myers Squibb | 150 | 2023-12-22 | 2026-09-30 | |
| Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg) - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 3 | Completed | Cytokinetics | 175 | 2023-06-20 | 2026-06-09 |
| Mavacamten in Obstructive Hypertrophic Cardiomyopathy Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | Bristol-Myers Squibb | 163 | 2023-02-21 | 2025-09-11 | |
| Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 3 | Completed | Cytokinetics | 282 | 2022-02-01 | 2026-03-03 |
| Left Ventricular Mass Index Predicts Clinical Outcomes in Patients with Obstructive Hypertrophic Cardiomyopathy Undergoing Septal Myectomy Patients had a higher left ventricular mass index or not （the exact value is determined by the cut-off value for the clinical outcomes) - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | Changrong Nie | 490 | 2011-06-01 | 2024-09-24 |
Cardiomyopathy, Hypertrophic (14) · Ventricular Outflow Obstruction, Left (1)
Aortic Stenosis, Subvalvular (14) · Aortic Valve Disease (14) · Aortic Valve Stenosis (14) · Cardiomyopathies (14) · Cardiovascular Diseases (14) · Heart Diseases (14) · Heart Valve Diseases (14) · Ventricular Outflow Obstruction (1)
MYK-461 (8) · Metoprolol (1)
Bristol-Myers Squibb (6) · Cytokinetics (2) · Assistance Publique - Hôpitaux de Paris (1) · Changrong Nie (1) · China National Center for Cardiovascular Diseases (1) · Chinese Academy of Medical Sciences, Fuwai Hospital (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Second Affiliated Hospital of Nanchang University (1)
China (7) · United States (4) · France (3) · United Kingdom (3) · Canada (2) · Denmark (2) · Germany (2) · Hungary (2) · Israel (2) · Italy (2) · Netherlands (2) · Spain (2) · Brazil (1) · Czechia (1) · Japan (1)
PMID 42624353, PMID 38032573, PMID 38739079, PMID 39056349, PMID 39217447, PMID 39217556, PMID 39217563, PMID 39217569, PMID 39230885, PMID 39352339, PMID 39909646, PMID 40200648, PMID 40888697, PMID 40910168, PMID 40932433, PMID 41347307, PMID 41348072, PMID 41493295, PMID 42307914, PMID 42667283
2023 (1)